Press Releases

Feb 26, 2026

Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

Feb 25, 2026

Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

Feb 11, 2026

Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET

Jan 29, 2026

Soleno Therapeutics to Participate in Upcoming Conferences

Jan 12, 2026

Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results

Jan 05, 2026

Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism

Dec 03, 2025

Soleno Therapeutics Announces the Passing of Board Member William G. Harris

Nov 24, 2025

Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 11, 2025

Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement

Nov 04, 2025

Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR